127 related articles for article (PubMed ID: 3544691)
1. Glucose tolerance in patients undergoing continuous ambulatory peritoneal dialysis.
Lindholm B; Karlander SG
Acta Med Scand; 1986; 220(5):477-83. PubMed ID: 3544691
[TBL] [Abstract][Full Text] [Related]
2. Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD.
Cheng SC; Chu TS; Huang KY; Chen YM; Chang WK; Tsai TJ; Wu KD
Perit Dial Int; 2001; 21(3):282-9. PubMed ID: 11475344
[TBL] [Abstract][Full Text] [Related]
3. Glucose metabolism in patients on continuous ambulatory peritoneal dialysis (CAPD).
Lindholm B; Bergström J; Karlander SG
Trans Am Soc Artif Intern Organs; 1981; 27():58-60. PubMed ID: 7036504
[No Abstract] [Full Text] [Related]
4. The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease.
Tuzcu A; Bahceci M; Yilmaz ME; Turgut C; Kara IH
Saudi Med J; 2005 May; 26(5):786-91. PubMed ID: 15951871
[TBL] [Abstract][Full Text] [Related]
5. Effect of dialysate glucose load on plasma glucose and glucoregulatory hormones in CAPD patients.
Armstrong VW; Creutzfeldt W; Ebert R; Fuchs C; Hilgers R; Scheler F
Nephron; 1985; 39(2):141-5. PubMed ID: 3883205
[TBL] [Abstract][Full Text] [Related]
6. Twenty-four hour hormonal and metabolic profiles in uraemic patients before and during treatment with continuous ambulatory peritoneal dialysis.
Heaton A; Johnston DG; Haigh JW; Ward MK; Alberti KG; Kerr DN
Clin Sci (Lond); 1985 Oct; 69(4):449-57. PubMed ID: 4042546
[TBL] [Abstract][Full Text] [Related]
7. Intermediary metabolism and glycemic control in insulin-dependent diabetic uremic patients treated by continuous peritoneal dialysis.
Spotti D; Slaviero G; La Rocca E; Cantaluppi A; Castelnovo C; Micossi P; Quartagno R; Melandri M; Pozza G; Ponticelli C
Nephron; 1988; 49(3):219-22. PubMed ID: 3041295
[TBL] [Abstract][Full Text] [Related]
8. Continuous ambulatory peritoneal dialysis in diabetes mellitus. The risks and benefits of intraperitoneal insulin.
Madden MA; Zimmerman SW; Simpson DP
Am J Nephrol; 1982; 2(3):133-9. PubMed ID: 6758585
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD.
Lin SH; Lin YF; Kuo SW; Hsu YJ; Hung YJ
Am J Kidney Dis; 2003 Oct; 42(4):774-80. PubMed ID: 14520628
[TBL] [Abstract][Full Text] [Related]
10. Fructosamine levels in CAPD: its value as glycemic index.
Coronel F; Macia M; Cidoncha A; Sanchez A; Tornero F; Barrientos A; Valor R
Adv Perit Dial; 1991; 7():253-6. PubMed ID: 1680438
[TBL] [Abstract][Full Text] [Related]
11. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose.
Heimbürger O; Stenvinkel P; Berglund L; Tranoeus A; Lindholm B
Nephron; 1996; 72(2):135-44. PubMed ID: 8684516
[TBL] [Abstract][Full Text] [Related]
12. Insulin therapy in uremic diabetic patients on continuous ambulatory peritoneal dialysis; comparison of intraperitoneal and subcutaneous administration.
Scarpioni L; Ballocchi S; Castelli A; Scarpioni R
Perit Dial Int; 1994; 14(2):127-31. PubMed ID: 8043664
[TBL] [Abstract][Full Text] [Related]
13. [Continuous ambulatory peritoneal dialysis treatment and blood glucose control in diabetics with end-stage diabetic nephropathy].
Li GW; Liu J; Chen L
Zhonghua Nei Ke Za Zhi; 1989 Jun; 28(6):360-3, 382. PubMed ID: 2684575
[TBL] [Abstract][Full Text] [Related]
14. [Biochemical changes with continuous ambulant peritoneal dialysis (CAPD)].
Fuchs C; Armstrong VW; Dorn D; Ebert R; Scheler F
Z Urol Nephrol; 1982 Jun; 75(6):415-27. PubMed ID: 6750973
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein (a) levels in patients undergoing continuous ambulatory peritoneal dialysis.
Guindeo C; Vega N; Fernandez AM; Palop L; Aguilar JA; Moreda A; Cia P
Perit Dial Int; 1996; 16 Suppl 1():S236-40. PubMed ID: 8728199
[TBL] [Abstract][Full Text] [Related]
16. Glucose, insulin and glucagon response to intravenous glucose load in patients on chronic hemodialysis.
Shasha SM; Nusem D; Kanter Y; Weiner F
Isr J Med Sci; 1988 Jan; 24(1):15-9. PubMed ID: 3279011
[TBL] [Abstract][Full Text] [Related]
17. Pre-dialysis glycemic control is an independent predictor of mortality in type II diabetic patients on continuous ambulatory peritoneal dialysis.
Wu MS; Yu CC; Wu CH; Haung JY; Leu ML; Huang CC
Perit Dial Int; 1999; 19 Suppl 2():S179-83. PubMed ID: 10406515
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of recombinant human erythropoietin therapy on growth hormone secretion in uremic patients undergoing peritoneal dialysis.
Díez JJ; Iglesias P; Sastre J; Aguilera A; Bajo MA; Méndez J; Gómez Pan A; Selgas R
Metabolism; 1999 Feb; 48(2):210-6. PubMed ID: 10024084
[TBL] [Abstract][Full Text] [Related]
19. Blood glucose and cholesterol control improved by continuous ambulatory peritoneal dialysis in patients with end-stage renal disease and diabetes mellitus.
Wikdahl AM; Granbom L; Sörensen JG; Stegmayr BG
Perit Dial Int; 1993; 13 Suppl 2():S239-41. PubMed ID: 8399577
[TBL] [Abstract][Full Text] [Related]
20. Diabetes, intraperitoneal insulin, and CAPD.
Cohen IM; Lee S
Clin Exp Dial Apheresis; 1981; 5(3):269-75. PubMed ID: 7037250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
